Drug Profile
Ritlecitinib - Pfizer
Alternative Names: LITFULO; Litfulo; PF 06651600; PF 6651600; Ritlecitinib tosilate - Pfizer; Ritlecitinib tosylate - PfizerLatest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer National Institute of Diabetes and Digestive and Kidney Diseases; Pfizer
- Class Amines; Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Antiulcers; Heterocyclic bicyclo compounds; Ketones; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Emt protein-tyrosine kinase inhibitors; Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alopecia areata
- Phase III Ulcerative colitis; Vitiligo
- Phase II Coeliac disease; Crohn's disease; Type 1 diabetes mellitus
- Discontinued Rheumatoid arthritis
Most Recent Events
- 17 Apr 2024 Pfizer plans to initiate a phase I trial (In volunteers) in May 2024 (PO) (NCT06369454)
- 28 Mar 2024 Pfizer completes a phase I pharmacokinetics trial (In volunteers) in Belgium (PO) (NCT06172348)
- 01 Feb 2024 Pfizer initiates a phase I pharmacokinetics trial (In volunteers) in Belgium (PO) (NCT06172348)